Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis

作者：Qingcheng Du, Guanming Jiang, Silu Li, Yong Liu, Zunnan Huang · 发表于：Oncoscience · 年份：2018 · DOI：10.18632/oncoscience.444 · 被引用次数：14 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Lung Cancer Research Studies

The purpose of this study was to determine whether docetaxel increases the risk of severe infections in patients with non-small cell lung cancer.A thorough literature search of the PubMed, EMBASE and Cochrane Central Register of Controlled Trials databases was performed (up to February 28, 2017) without any language restrictions.In addition, we searched the www.clinicaltrials.govwebsite and checked each reference listed in the included studies, relevant reviews and guidelines.We also included randomized controlled trials that reported severe infections in patients with non-small cell lung cancer who were administered docetaxel.A metaanalysis was conducted using relative risk and random effects models in Stata 14.0 software.Sensitivity analysis and meta-regression were performed using Stata 14.0 software.We identified 354 records from the initial search, and this systematic review ultimately included 43 trials with 12,447 participants.The results of our metaanalysis showed that docetaxel increased the risk of severe infections [relative risk: 2.10, 95% confidence interval: 1.51-2.93,I 2 = 69.6%,P = 0.000].Meta-regression analysis indicated that the type of intervention was a major source of heterogeneity.Our systematic review and meta-analysis suggest that docetaxel is associated with the risk of severe infections.